6.74
-0.11(-1.61%)
Currency In USD
Address
100 High Street
Boston, MA 02110
United States of America
Phone
617 349 1971
Website
Sector
Healthcare
Industry
Biotechnology
Employees
78
First IPO Date
June 25, 2015
| Name | Title | Pay | Year Born |
| Ms. Jill C. Milne Ph.D. | Co-Founder, Chief Executive Officer, President & Director | 967,338 | 1968 |
| Mr. Noah C. Clauser CPA | Chief Financial Officer & Treasurer | 621,406 | 1974 |
| Mr. Benjamin S. Harshbarger J.D. | Chief Legal Officer | 658,041 | 1969 |
| Dr. Christopher J. Morabito M.D. | Chief Medical Officer | 690,824 | 1970 |
| Mr. Andrew A. Komjathy | Chief Commercial Officer | 0 | 1963 |
| Ms. Keri McGrail | Chief Human Resources Officer | 0 | N/A |
| Ms. Andrea L. Matthews | Chief Business Officer | 0 | 1982 |
| Mr. John Ruesch | Senior Vice President of Pharmaceutical Sciences & Technical Operations | 0 | N/A |
| Ms. Rafif Dagher | Senior Vice President and Head of Discovery, Nonclinical Development & Translational Research | 0 | N/A |
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.